Dr. Nicole Lamanna, MD
Claim this profileColumbia University Medical Center
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
6 reported clinical trials
9 drugs studied
Area of expertise
1Lymphoma
13q positive
13q negative
12 positive
2Chronic Lymphocytic Leukemia
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Nicole Lamanna, MD is currently running
Venetoclax
for Chronic Lymphocytic Leukemia
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.
Recruiting1 award Phase 2
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Nicole Lamanna, MD
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Nicole Lamanna, MD has experience with
- Venetoclax
- Rituximab
- Bendamustine
- Cirmtuzumab
- Ibrutinib
- MS-553
Breakdown of trials Nicole Lamanna, MD has run
Lymphoma
Chronic Lymphocytic Leukemia
Childhood Cancer
Mantle Cell Lymphoma
MALT Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicole Lamanna, MD specialize in?
Nicole Lamanna, MD focuses on Lymphoma and Chronic Lymphocytic Leukemia. In particular, much of their work with Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Nicole Lamanna, MD currently recruiting for clinical trials?
Yes, Nicole Lamanna, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Nicole Lamanna, MD has studied deeply?
Yes, Nicole Lamanna, MD has studied treatments such as Venetoclax, Rituximab, Bendamustine.
What is the best way to schedule an appointment with Nicole Lamanna, MD?
Apply for one of the trials that Nicole Lamanna, MD is conducting.
What is the office address of Nicole Lamanna, MD?
The office of Nicole Lamanna, MD is located at: Columbia University Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.